Bio-Business in Brief: The Debate Over Biosimilars
Current cience, 98, 1575-1578, 2010
Posted: 28 Jan 2016 Last revised: 26 Feb 2016
Date Written: June 25, 2010
Abstract
Biosimilars are the subject of much debate: should they be allowed or not? Some of the issues are discussed here. Also those approved in Europe and India are listed.
(Article freely downloadable from the journal website.)
Keywords: Biotechnology, biosimilars, drug company, follow on biologics, pharma industry
JEL Classification: I10, O32, O51, O52, O53
Suggested Citation: Suggested Citation
Saberwal, Gayatri, Bio-Business in Brief: The Debate Over Biosimilars (June 25, 2010). Current cience, 98, 1575-1578, 2010, Available at SSRN: https://ssrn.com/abstract=2723893
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.